POS1354 GENDER DIFFERENCES IN CLINICAL FEATURES AND BURDEN IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: PRELIMINARY REPORT

Background: Familial Mediterranean fever (FMF) is the most common hereditary auto-inflammatory disease, which more in groups basin, characterized by recurrent attacks of febrile peritonitis, pleuritis and arthritis. Objectives: The aim this study to investigate gender differences clinical demographic features patients with familial (FMF). Methods: Patients FMF diagnosed according Tel-Hashomer criteria were included multi-center study. Data about age, sex, disease duration, symptom age at diagnosis, comorbid diseases medications noted. All screen Hospital Anxiety Depression Scale (HADS), Health Assessment Questionnaires (HAQ), Short Form 36 (SF-36). severity was assessed PRASS scoring system. Results: Of 286 patients, 199 (69,6%) female mean 36,2(SD:12.32) years 87 (30,4%) male 32,9(SD:12,6) (p=0,017). Age diagnosis lower than females (p=0,008). genetic mutation both genders M694V gene mutation. Homozygous positivity higher males (31,79% vs 17,4%). More 90% receiving colchicine,10 (3,5%) anakinra 5(1,75%) canakinumab. Among regularly taking colchicine, 86.2% 86% (p=0,981). There no between terms findings, frequency duration attacks, presence colchicine resistance, amyloidosis (p>0.05). ESR detected group (p=0,011). Headache (p=0,001), migraine (p=0,031), concomitant (p=0,017) also males. depression scores (p<0,05). activity similar (p>0,05). parameters SF-36 while HAQ score Conclusion: Although treatment compliance are genders, earlier females, but findings such as anxiety, depression, migraine, headache patients. References: [1]Doğan HO, Koca Y, Erden G, Karaaslan Bozat H. Evaluating MEFV Turkish suspected correlation: a retrospective Mol Biol Rep. 2012 May;39(5):6193-6. Table 1. Demographic Female (n:199 ) Male (n:87 P features, (SD 36,2 (12.32) 32,9 (12,6) 0,017 BMI 26,87(5,73) 25,79(5,28) 0,177 Educational level, 8,77(4,36) 12,08(3,23) 0,000 28 (13,31) 23,7 (13,42) 0,008 onset 19,2 17 (10,6) 0,265 Clinical n (% Fever 166 (83,4) 77 (88,5) 0,268 Abdominal pain 180 (90,5) 78 (89,7) 0,835 Chest 62 (31,2) 20 (23) 0,160 Erysipelas like erythema 12 (6) 4 (4) 0,628 Arthritis 46 (23,1) 24 (24) 0,419 Arthralgia 102 (51,3) 42 (48,3) 0,643 Myalgia 101 (50,8) 47 (54) 0,611 MEVF mutations, M694V/M694V (12.3) 19 (22) 0.047 h eterozygous 38 (19,5) 14 (16,3) 0.523 M694V/any 25 (12,8) 15 (17,4) 0.307 severity, 0,813 Mild 99(49,7) 46(52,9) Moderate 88(44,2) 35(40,2) Severe 12(6) 6(6,9) ESR, mm/hour, 23,77(16,27) 18,25(18,41) 0,011 HAQ, 0,49 (0,63) 0,16 (0,43) HAD, 8,4 (4,4) 6,7 (3,44) 0,003 7,1 (4,27) 5,7 (3,81) 0,006 SF-36, Physical functioning 63,56 (23,81) 79,93 (19,32) role limitation 45,78 (40,95) 61,41 (39,14) Emotional 47,36 (42,04) 66,20 (40,69) 0,020 Energy/fatigue 42,50 (20,64) 53,64 (19,82) well-being 51,61 (18,47) 58,74 (18,30) Social 57,06 (23,09) 70,52 (23,82) Pain 51,66 (24,05) 65,72 (24,51) General health 39,53 (20,01) 52,46 (23,83) Disclosure Interests: None declared